Literature DB >> 8187206

Intracellular processing of apo(a) in primary baboon hepatocytes.

A L White1, D L Rainwater, J E Hixson, L E Estlack, R E Lanford.   

Abstract

We have developed a serum-free medium for the long-term culture of highly differentiated primary baboon hepatocytes. Hepatocytes isolated from animals with defined plasma Lp(a) levels and apo(a) glycoprotein phenotypes were used to study the assembly of Lp(a). A combination of steady-state and pulse-chase labeling studies and endoglycosidase digests demonstrated that apo(a) was synthesized as a lower molecular weight precursor. After a prolonged period of time in the endoplasmic reticulum, apo(a) was converted to a mature form and secreted. A proportion of mature apo(a) also had a prolonged residence time in the trans Golgi apparatus. In all experiments, apoB co-immunoprecipitated with apo(a) from the culture medium but not from the cell lysates, supporting an extracellular association of the proteins for the formation of Lp(a). Analysis of hepatic RNA from 29 'null' Lp(a) phenotype baboons revealed that one-third of the animals had detectable apo(a) transcripts, whereas the remainder had no detectable apo(a) mRNA. The baboon hepatocyte system therefore represents a valuable model to examine the effect of allelic variation at the apo(a) locus on Lp(a) assembly.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8187206     DOI: 10.1016/0009-3084(94)90131-7

Source DB:  PubMed          Journal:  Chem Phys Lipids        ISSN: 0009-3084            Impact factor:   3.329


  9 in total

1.  Nonsynonymous SNPs in LPA homologous to plasminogen deficiency mutants represent novel null apo(a) alleles.

Authors:  Benjamin M Morgan; Aimee N Brown; Nikita Deo; Tom W R Harrop; George Taiaroa; Peter D Mace; Sigurd M Wilbanks; Tony R Merriman; Michael J A Williams; Sally P A McCormick
Journal:  J Lipid Res       Date:  2019-12-05       Impact factor: 5.922

2.  Sortilin enhances secretion of apolipoprotein(a) through effects on apolipoprotein B secretion and promotes uptake of lipoprotein(a).

Authors:  Justin R Clark; Matthew Gemin; Amer Youssef; Santica M Marcovina; Annik Prat; Nabil G Seidah; Robert A Hegele; Michael B Boffa; Marlys L Koschinsky
Journal:  J Lipid Res       Date:  2022-04-22       Impact factor: 6.676

Review 3.  Lipoprotein(a) metabolism: potential sites for therapeutic targets.

Authors:  Jane Hoover-Plow; Menggui Huang
Journal:  Metabolism       Date:  2012-10-04       Impact factor: 8.694

4.  Lipoprotein(a): biology and clinical importance.

Authors:  Sally P A McCormick
Journal:  Clin Biochem Rev       Date:  2004-02

5.  FGF21 inhibits apolipoprotein(a) expression in HepG2 cells via the FGFR1-ERK1/2-Elk-1 pathway.

Authors:  Xiaolong Lin; Guohua Li; Xinglan He; Xiaofeng Ma; Kai Zhang; Hai Zhang; Gaofeng Zeng; Zuo Wang
Journal:  Mol Cell Biochem       Date:  2014-04-04       Impact factor: 3.396

Review 6.  Beyond Lipoprotein(a) plasma measurements: Lipoprotein(a) and inflammation.

Authors:  Gissette Reyes-Soffer; Marit Westerterp
Journal:  Pharmacol Res       Date:  2021-05-23       Impact factor: 10.334

7.  A genome-wide analysis of DNA methylation identifies a novel association signal for Lp(a) concentrations in the LPA promoter.

Authors:  Stefan Coassin; Natascha Hermann-Kleiter; Margot Haun; Simone Wahl; Rory Wilson; Bernhard Paulweber; Sonja Kunze; Thomas Meitinger; Konstantin Strauch; Annette Peters; Melanie Waldenberger; Florian Kronenberg; Claudia Lamina
Journal:  PLoS One       Date:  2020-04-28       Impact factor: 3.240

Review 8.  The metabolism of lipoprotein (a): an ever-evolving story.

Authors:  Gissette Reyes-Soffer; Henry N Ginsberg; Rajasekhar Ramakrishnan
Journal:  J Lipid Res       Date:  2017-07-18       Impact factor: 5.922

9.  Relations between lipoprotein(a) concentrations, LPA genetic variants, and the risk of mortality in patients with established coronary heart disease: a molecular and genetic association study.

Authors:  Stephen Zewinger; Marcus E Kleber; Vinicius Tragante; Raymond O McCubrey; Amand F Schmidt; Kenan Direk; Ulrich Laufs; Christian Werner; Wolfgang Koenig; Dietrich Rothenbacher; Ute Mons; Lutz P Breitling; Herrmann Brenner; Richard T Jennings; Ioannis Petrakis; Sarah Triem; Mira Klug; Alexandra Filips; Stefan Blankenberg; Christoph Waldeyer; Christoph Sinning; Renate B Schnabel; Karl J Lackner; Efthymia Vlachopoulou; Ottar Nygård; Gard Frodahl Tveitevåg Svingen; Eva Ringdal Pedersen; Grethe S Tell; Juha Sinisalo; Markku S Nieminen; Reijo Laaksonen; Stella Trompet; Roelof A J Smit; Naveed Sattar; J Wouter Jukema; Heinrich V Groesdonk; Graciela Delgado; Tatjana Stojakovic; Anna P Pilbrow; Vicky A Cameron; A Mark Richards; Robert N Doughty; Yan Gong; Rhonda Cooper-DeHoff; Julie Johnson; Markus Scholz; Frank Beutner; Joachim Thiery; J Gustav Smith; Ragnar O Vilmundarson; Ruth McPherson; Alexandre F R Stewart; Sharon Cresci; Petra A Lenzini; John A Spertus; Oliviero Olivieri; Domenico Girelli; Nicola I Martinelli; Andreas Leiherer; Christoph H Saely; Heinz Drexel; Axel Mündlein; Peter S Braund; Christopher P Nelson; Nilesh J Samani; Daniel Kofink; Imo E Hoefer; Gerard Pasterkamp; Arshed A Quyyumi; Yi-An Ko; Jaana A Hartiala; Hooman Allayee; W H Wilson Tang; Stanley L Hazen; Niclas Eriksson; Claes Held; Emil Hagström; Lars Wallentin; Axel Åkerblom; Agneta Siegbahn; Igor Karp; Christopher Labos; Louise Pilote; James C Engert; James M Brophy; George Thanassoulis; Peter Bogaty; Wojciech Szczeklik; Marcin Kaczor; Marek Sanak; Salim S Virani; Christie M Ballantyne; Vei-Vei Lee; Eric Boerwinkle; Michael V Holmes; Benjamin D Horne; Aroon Hingorani; Folkert W Asselbergs; Riyaz S Patel; Bernhard K Krämer; Hubert Scharnagl; Danilo Fliser; Winfried März; Thimoteus Speer
Journal:  Lancet Diabetes Endocrinol       Date:  2017-05-26       Impact factor: 32.069

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.